Asia Pacific Healthcare Bioconvergence Market Size & Outlook
Asia Pacific healthcare bioconvergence market, 2017-2030 (US$M)
Related Markets
Asia Pacific healthcare bioconvergence market highlights
- The Asia Pacific healthcare bioconvergence market generated a revenue of USD 32,857.5 million in 2022.
- The market is expected to grow at a CAGR of 8% from 2023 to 2030.
- In terms of segment, drug discovery was the largest revenue generating application in 2022.
- Nanorobotics for Drug Delivery is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, Japan is expected to register the highest CAGR from 2023 to 2030.
Asia Pacific data book summary
| Market revenue in 2022 | USD 32,857.5 million |
| Market revenue in 2030 | USD 60,696.4 million |
| Growth rate | 8% (CAGR from 2022 to 2030) |
| Largest segment | Drug discovery |
| Fastest growing segment | Nanorobotics for Drug Delivery |
| Historical data covered | 2017 - 2021 |
| Base year for estimation | 2022 |
| Forecast period covered | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Drug Discovery, Nanorobotics for Drug Delivery, Regenerative Medicine, Diagnostic and Biological, Bioelectronics, Engineered Living Materials, Optogenetics, Precision Medicine |
| Key market players worldwide | BiomX Inc, Ginkgo Bioworks Holdings Inc, SetPoint Medical, GSK PLC, BICO |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 27.0% of the global healthcare bioconvergence market in 2022.
- Globally, Europe is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 60,696.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Healthcare Bioconvergence Market Scope
Healthcare Bioconvergence Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific healthcare bioconvergence market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to healthcare bioconvergence market will help companies and investors design strategic landscapes.
Drug discovery was the largest segment with a revenue share of 19.68% in 2022. Horizon Databook has segmented the Asia Pacific healthcare bioconvergence market based on drug discovery, nanorobotics for drug delivery, regenerative medicine, diagnostic and biological, bioelectronics, engineered living materials, optogenetics, precision medicine covering the revenue growth of each sub-segment from 2017 to 2030.
- Asia Pacific Healthcare Bioconvergence Application Outlook (Revenue, USD Million, 2017-2030)
- Drug Discovery
- Nanorobotics for Drug Delivery
- Regenerative Medicine
- Diagnostic and Biological
- Bioelectronics
- Engineered Living Materials
- Optogenetics
- Precision Medicine
Reasons to subscribe to Asia Pacific healthcare bioconvergence market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific healthcare bioconvergence market databook
-
Our clientele includes a mix of healthcare bioconvergence market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific healthcare bioconvergence market, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific healthcare bioconvergence market from 2017 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific healthcare bioconvergence market report size, by country, 2017-2030 (US$M)
Asia Pacific Healthcare Bioconvergence Market Share, 2022 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
